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Results 
§  20 patients were recruited between July 2009 and August 2010 (13 received 
upgrade to TriV CRT and 7 did not receive upgrade of their biventricular 
CRT).  
§  Baseline characteristics (Table 1) were similar between the two groups except 
for the Minnesota Living with Heart Failure score (Trivent 62.0±25.0 vs 
Control 33.0±14.5, p=0.01). 
§  At 5 years, fewer patients in the upgrade to TriV group had worsened clinical 
response compared to the no upgrade group (38.5% vs 85.7%, p=0.04). 
§  At 5 years, the cumulative probability of survival was higher in the Upgrade to 
TriV group vs no upgrade group (Kaplan-Meier Method, Log-rank test, 
p=0.021). 
§  No difference was found in percentage improvement in LVEF or percentage 
reduction in LVESV between the 2 groups on echocardiography during follow 
up (no upgrade group: 19.0±21.2 months vs upgrade to TriV group: 25±17.9 
months; p=0.55). 
§  1 wound infection, 2 failures to upgrade and 1 lead displacement were 
observed in the upgrade to TriV group.  
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Conclusion 
 
§  Upgrade to tri-ventricular CRT in non-responders to biventricular CRT may 
potentially improve clinical response to CRT and long-term survival. 
§  The rate of procedural complications may reflect the risks associated with a 
complex upgrade procedure.  
§  Mechanism of survival benefit from upgrade to tri-ventricular CRT is not explained 
by LV ejection fraction or LV end systolic volume.  
§  These findings warrant further evaluation in a large randomized control trial.  
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Purpose 
§  Up to one third of patients with biventricular (BiV) cardiac resynchronization 
therapy (CRT) are non-responders.1  
§  Greater clinical response to CRT has been shown in patients given TriV CRT 
compared to BiV CRT as de novo device therapy. 2 This abstract investigates if 
upgrade to TriV CRT in non-responders to BiV CRT will improve long-term 
clinical outcome. 
Table 1. Baseline characteristics of non-responders to biventricular CRT: upgrade to TriV CRT vs no 
upgrade group. Continuous data expressed as mean ± SD or median and interquartile range for non-
parametric data. *p<0.05.  
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Methods 
§  Prospective randomized controlled study of non-responders to optimized, 
biventricualr CRT-pacemakers or CRT-defibrillators (at least 6 months of 
biventricular CRT) with New York Heart Association (NYHA) class III symptoms 
and left ventricular ejection fraction of ≤35%. 
§  The study conformed to the Declaration of Helsinki of the World Medical 
Association.  
§  Participants were randomized (2:1) to the upgrade to TriV CRT group or no 
upgrade group.  
§  Primary outcome was clinical response to CRT. Each patient was assessed for 
the worst outcome among the following categories of worsened clinical 
response: death from any cause, hospitalisation for heart failure, worsening of 
symptoms perceived by patients and worsening of NYHA class perceived by 
health professionals. Subjects were included only in one subcategory.  
§  Secondary outcomes were all-cause mortality and procedural complications. LV 
ejection fraction (LVEF) and LV end systolic volume (LVESV) were compared 
between the 2 groups on the last available echocardiogram during follow up.  
§  Censor date was on 13th January 2015. 
Variable	   No	  upgrade	  	  (n=7)	  
Upgrade	  to	  TriV	  
CRT	  (n=13)	  
P-­‐value	  (2-­‐
tailed)	  
Age	  (years)	  	   70.4±9.3	   64.5±11.9	   0.27	  
Gender	  (male)	  (%)	   5	  (71.4)	   10	  (76.9)	   0.79	  	  
Time	  since	  BiV	  CRT	  (months)	   21	  (IQ	  12-­‐32)	   18	  (IQ	  13-­‐45.5)	   0.70	  
Ischaemic	  heart	  failure	  (%)	   4	  (57.1)	   8	  (61.5)	   0.85	  
NYHA:	  Class	  III	  (%)	   7	  (100)	   13	  (100)	   1.0	  
Atrial	  arrhythmias	  (%)	   3	  (42.9)	   1	  (7.7)	   0.06	  
Intrinsic	  PR	  or	  AR	  interval	  (ms)	   250.0±26.9	   180±60	   0.09	  
BiV	  QRS	  duraOon	  (ms)	  
Intrinsic	  QRS	  duraOon	  (ms)	  
158.2±24.0	  
154.8±16.8	  
153.5±14.5	  
148.4±23.6	  
0.61	  
0.60	  
Minnesota	  Living	  with	  Heart	  
Failure	  score	   33.0±14.5	   62±25.0	   *0.01	  
Heart	  failure	  medicaOon	  (%):	  
-­‐Beta-­‐blocker	  
-­‐ACEi	  or	  ARB	  
-­‐Spironolactone	  
-­‐DiureOcs	  
	  
5	  (71.4)	  
6	  (85.7)	  
3	  (42.9)	  
6	  (85.7)	  
	  
11	  (84.6)	  
13	  (100)	  
8	  (61.5)	  
13	  (100)	  
0.48	  
0.16	  
0.42	  
0.16	  
Percentage	  BiV	  pacing	  (%)	   99	  (IQ94-­‐99)	   99.5	  (IQ94.8-­‐100)	   0.34	  
Old	  LV	  lead	  in	  posterolateral	  or	  
lateral	  CS	  branch	  (%)	   3	  (42.9)	   7	  (53.8)	   0.60	  
LVEF	  (%)	   26.8±5.6	   27.1±6.2	   0.95	  
LVESV	  (ml)	   125.1±60.0	   128.9±43.4	   0.91	  
*p=0.043 
P=0.87 
Fig. 1. Four patients in the 
upgrade to TriV CRT group 
underwent non-contact 
mapping of the left ventricle 
(LV) with the EnSite 3000 Array 
catheter to study the LV 
activation time from BiV and 
TriV pacing in different CS 
branches prior to the upgrade. 
Fig. 1 A to 1D were obtained 
from the same patient. Fig. 1A: 
CXR prior to upgrade of BiV 
CRT. Fig. 1B: CS venogram 
showing the anteroseptal vein 
(yellow arrow). Fig. 1C: 
Fluoroscopy image showing the 
Ensite 3000 Array catheter for 
non-contact mapping of the LV 
(green arrow) and the pacing 
wire in a new site in the 
anteroseptal CS branch (blue 
arrow). Fig. 1D: CXR after 
upgrade of BiV to TriV CRT.  
A B 
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Fig. 2. Percentage improvement in LVEF on 
echocardiography at follow up in the no upgrade of 
BiV group Vs upgrade to TriV CRT group,  
Fig. 3. Percentage reduction in LV end systolic 
volume (LVESV) on echocardiography at follow up 
in the no upgrade of BiV group Vs upgrade to TriV 
CRT group,  
Fig. 5. Clinical response to CRT at 5 years in non-
responders to CRT: upgrade to TriV CRT vs no 
upgrade. *p<0.05 Chi-squared test.  
P=0.88 
Fig. 4. Cumulative probability of survival at 5 years in 
non-responders to biventricular CRT: upgrade to tri-
ventricular CRT (TRIVENT) group vs no upgrade 
(Control). Kaplan-Meier Method, Log-rank test, 
*p<0.05. 
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